Regeneron’s antibody drug shows protection against Covid for up to 8 months

Regeneron Pharmaceuticals said on Monday a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in a late-stage trial, in the two to eight months period following the drug’s administration.The data is expected to support the ongoing regulatory review to extend the antibody therapy’s use in preventing Covid in…

Share this: